Drug intelligence / Profile preview

dimetotiazine

Development stage
Unknown
Modality
Small Molecules
Administration
Oral, Intramuscular
01

Overview

Dimetotiazine is a small molecule drug belonging to the phenothiazine class, primarily used as an antimigraine agent and for its antiemetic and antihistamine properties. It acts as a serotonin receptor antagonist and histamine H1 receptor antagonist, blocking the effects of endogenous serotonin and histamine. This mechanism underlies its effectiveness in treating migraine, allergic skin conditions, nausea, vomiting (including that associated with chemotherapy), and other symptoms related to excessive serotonergic or histaminergic activity. Dimetotiazine has been marketed in Japan and Europe under brand names such as Fonazine and Migristene for the treatment of migraine disorders[3][4][7].

Brand names
FonazineMigristene
Other names
dimethothiazinedimetotiazine mesilatefonazine mesylatedimetotiazinumdimetotiazina
02

Targets

HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)HTR2B (5-Hydroxytryptamine Receptor 2B)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on dimetotiazine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on dimetotiazine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call